Related Experiment Video
Updated: Apr 3, 2026

Murine Ileocolic Bowel Resection with Primary Anastomosis
Published on: October 29, 2014
Postsurgical Prophylaxis in Crohn's Disease: Which Patients, Which Agents?
Crohn's disease recurrence after surgery is common. Early, aggressive medical therapy, including anti-tumor necrosis factor (anti-TNF) agents, is crucial for high-risk patients to prevent relapse and manage inflammation.
Area of Science:
- Gastroenterology
- Immunology
- Surgical Oncology
Background:
- Crohn's disease (CD) frequently recurs post-surgery, with up to 60% of patients experiencing relapse within a year.
- Complications like strictures, abscesses, and fistulas necessitate surgical intervention, yet recurrence rates remain high.
- Identifying patients at high risk for postsurgical CD recurrence is critical for effective management.
Purpose of the Study:
- To review current strategies for preventing and managing postsurgical Crohn's disease recurrence.
- To highlight the importance of risk stratification and timely initiation of prophylactic medical therapy.
- To discuss the evolving role of various therapeutic agents and monitoring techniques.
Main Methods:
- Review of existing literature on Crohn's disease recurrence and management post-resection.
- Analysis of risk factors associated with postsurgical recurrence.
- Evaluation of the efficacy of different prophylactic medical therapies, including immunosuppressors, anti-tumor necrosis factor (anti-TNF) agents, and emerging treatments.
- Discussion of monitoring strategies such as endoscopy and noninvasive markers.
Main Results:
- Young age, smoking, repeat surgeries, and penetrating disease are key risk factors for recurrence.
- Aggressive therapies like thiopurines and anti-TNF agents demonstrate higher efficacy than traditional treatments.
- Early initiation of immunosuppressive or anti-TNF therapy in high-risk patients is recommended.
- Endoscopic monitoring is vital, as endoscopic recurrence often precedes clinical relapse.
Conclusions:
- A step-up approach, starting with immunosuppressors or imidazole antibiotics and escalating to anti-TNF agents, is the current standard.
- Risk stratification and prompt, aggressive prophylactic treatment are essential to minimize postsurgical Crohn's disease recurrence.
- Further research into novel agents like anti-homing therapies may offer future therapeutic benefits.
More Related Videos
07:06Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
05:32Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
Published on: September 21, 2015
Related Concept Videos
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...